Fusion Antibodies (FAB) Competitors

Fusion Antibodies (LON:FAB) and IXICO (LON:IXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings, valuation and community ranking.

Which has more volatility & risk, FAB or IXI?

Fusion Antibodies has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, IXICO has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Which has better valuation and earnings, FAB or IXI?

IXICO has higher revenue and earnings than Fusion Antibodies. IXICO is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fusion Antibodies	£1.58M	2.26	-£2.84M	-£0.09	-41.67
IXICO	£6.67M	0.63	-£1.18M	-£0.02	-437.50

Does the media favor FAB or IXI?

In the previous week, IXICO had 1 more articles in the media than Fusion Antibodies. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Fusion Antibodies. IXICO's average media sentiment score of 0.99 beat Fusion Antibodies' score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company	Overall Sentiment
Fusion Antibodies	Neutral
IXICO	Positive

Do analysts rate FAB or IXI?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fusion Antibodies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
IXICO	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Do insiders and institutionals hold more shares of FAB or IXI?

24.4% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 56.9% of IXICO shares are owned by institutional investors. 10.4% of Fusion Antibodies shares are owned by insiders. Comparatively, 29.0% of IXICO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community favor FAB or IXI?

IXICO received 90 more outperform votes than Fusion Antibodies when rated by MarketBeat users. Likewise, 71.64% of users gave IXICO an outperform vote while only 68.35% of users gave Fusion Antibodies an outperform vote.

Company	Underperform	Outperform
Fusion Antibodies	Outperform Votes 54 68.35%	Underperform Votes 25 31.65%
IXICO	Outperform Votes 144 71.64%	Underperform Votes 57 28.36%

Is FAB or IXI more profitable?

IXICO has a net margin of -17.67% compared to Fusion Antibodies' net margin of -179.67%. IXICO's return on equity of -9.85% beat Fusion Antibodies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fusion Antibodies	-179.67%	-140.93%	-62.52%
IXICO	-17.67%	-9.85%	-6.50%

Summary

IXICO beats Fusion Antibodies on 13 of the 15 factors compared between the two stocks.